Replimune Group (REPL) News Today $8.80 +0.38 (+4.51%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.66 -0.14 (-1.53%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period The Best AI for Picking Stocks, Ranked by Performance (REPL)AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.October 23 at 2:38 PM | marketbeat.comReplimune Group FY2027 EPS Decreased by Leerink PartnrsOctober 23 at 8:02 AM | marketbeat.comReplimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?October 22 at 3:54 PM | finance.yahoo.comWedbush Issues Positive Outlook for Replimune Group EarningsOctober 22 at 8:20 AM | marketbeat.comBarclays Keeps Their Hold Rating on Replimune Group (REPL)October 22 at 7:42 AM | theglobeandmail.comJP Morgan Upgrades Replimune Group (REPL)October 21, 2025 | msn.comWedbush Upgrades Replimune Group (REPL)October 21, 2025 | msn.comA Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial ResultsOctober 21, 2025 | finance.yahoo.comLeerink Partnrs Upgrades Replimune Group (NASDAQ:REPL) to "Strong-Buy"October 21, 2025 | marketbeat.comReplimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)October 21, 2025 | seekingalpha.comReplimune Group, Inc. $REPL Shares Bought by TD Asset Management IncOctober 21, 2025 | marketbeat.comWhy Replimune Stock Was Soaring TodayOctober 20, 2025 | fool.comReplimune Group (NASDAQ:REPL) Upgraded by Piper Sandler to "Overweight" RatingOctober 20, 2025 | marketbeat.comPromising Biotech Stocks To Follow Now - October 20thOctober 20, 2025 | marketbeat.comJPMorgan Chase & Co. Upgrades Replimune Group (NASDAQ:REPL) to "Neutral"October 20, 2025 | marketbeat.comWhat Is Driving Replimune Stock’s 98% Surge Today?October 20, 2025 | msn.comReplimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst UpgradeOctober 20, 2025 | marketbeat.comLeerink Partners Upgrades Replimune Group (NASDAQ:REPL) to "Outperform"October 20, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Upgraded at WedbushOctober 20, 2025 | marketbeat.comReplimune stock soars after FDA accepts BLA resubmission for melanoma drugOctober 20, 2025 | za.investing.comReplimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma TherapyOctober 20, 2025 | msn.comReplimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced MelanomaOctober 20, 2025 | globenewswire.comReplimune announces new ad hoc analysis from IGNYTE phase 2 cohort of RP1October 19, 2025 | msn.comReplimune Group, Inc. Shares Promising Data on RP1 and Nivolumab Combination for Acral Melanoma at ESMO Congress 2025October 19, 2025 | quiverquant.comQReplimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025October 19, 2025 | markets.businessinsider.comReplimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025October 19, 2025 | globenewswire.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Replimune Group (NASDAQ:REPL)October 16, 2025 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Given Sell (D-) Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comREPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 8, 2025 | globenewswire.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comReplimune Group (REPL) Receives a Hold from BarclaysSeptember 25, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLSeptember 23, 2025 | prnewswire.comInvestors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPLSeptember 22, 2025 | globenewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneSeptember 22, 2025 | businesswire.comREPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law FirmSeptember 22, 2025 | prnewswire.comReplimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPLSeptember 22, 2025 | prnewswire.comReplimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPLSeptember 22, 2025 | prnewswire.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 22, 2025 | prnewswire.comReplimune Group (REPL) Gets a Hold from BarclaysSeptember 21, 2025 | theglobeandmail.comREPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 21, 2025 | globenewswire.comREPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens BermanSeptember 21, 2025 | globenewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneSeptember 21, 2025 | globenewswire.comREPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPLSeptember 21, 2025 | globenewswire.comREPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities ...September 21, 2025 | tmcnet.comReplimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit AnnouncementsSeptember 21, 2025 | finance.yahoo.comREPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPLSeptember 20, 2025 | businesswire.comReplimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens BermanSeptember 20, 2025 | prnewswire.comReplimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' RatingSeptember 20, 2025 | seekingalpha.comJPMorgan Chase & Co. Reiterates "Underweight" Rating for Replimune Group (NASDAQ:REPL)September 20, 2025 | marketbeat.comReplimune stock plunges after FDA meeting fails to clear path forwardSeptember 19, 2025 | za.investing.com Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPL Media Mentions By Week REPL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.920.93▲Average Medical News Sentiment REPL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼3712▲REPL Articles Average Week Get the Latest News and Ratings for REPL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Replimune Group and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Zymeworks News Evotec News Immunome News Spyre Therapeutics News Amylyx Pharmaceuticals News Taysha Gene Therapies News Enliven Therapeutics News Trevi Therapeutics News WAVE Life Sciences News Oric Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
